K

G

Goldman Sachs Alternatives

Crunchbase
Crunchbase

Deals on record

15

Common Fundraising Type

Series B

F
Fleetio

Fleet optimization • Software

Goldman Sachs Alternatives logo
Elephant logo

Fleetio provides fleet optimization software to enhance vehicle and asset management for fleets globally.

Series D
$450M
03/25/2025
Article
N
Navina

AI • Clinical intelligence

Vertex Ventures Israel logo
Grove Ventures logo
Goldman Sachs Alternatives logo
ALIVE logo

Navina provides AI-powered clinical intelligence solutions that transform fragmented patient data into actionable insights to aid clinicians and care teams in improving patient care and reducing administrative burdens.

Series C
$55M
03/25/2025
Article
S
SkySpecs

Renewable energy • Asset management

SkySpecs provides renewable energy asset health management solutions using autonomous drones and blade data to optimize wind farm performance and manage risks.

Equity
$20M
03/20/2025
Article
M
Mews

Hospitality • Cloud platform

Tiger Global logo
Kinnevik logo
Goldman Sachs Alternatives logo
Battery Ventures logo

Mews provides a cloud-based property management system designed to streamline hotel operations and enhance the guest experience.

Equity
$75M
03/04/2025
Article
T
Trackunit

SaaS • IoT

Goldman Sachs Alternatives logo
Hg logo

Trackunit provides a SaaS and IoT connectivity platform for the construction industry.

Equity
Undisclosed
02/21/2025
Article
7
73 Strings

AI-powered data extraction • Portfolio monitoring

Hamilton Lane logo
Goldman Sachs Alternatives logo
Golub Capital logo
Broadhaven Ventures logo

73 Strings provides AI-powered data extraction, portfolio monitoring, and valuation solutions for the private capital markets.

Series B
$55M
02/19/2025
Article
H
Hydrostor

Energy storage • Compressed air

Canada Growth Fund logo
Goldman Sachs Alternatives logo
Canada Pension Plan Investment Board logo

Hydrostor develops long-duration energy storage systems using Advanced Compressed Air Energy Storage (A-CAES) technology.

Hybrid
$200M
02/13/2025
Article
N
Newleos Therapeutics

Neuroscience • Clinical-stage

Novo Holdings logo
Longwood Fund logo
Goldman Sachs Alternatives logo
DCVC Bio logo

Newleos Therapeutics is a clinical-stage neuroscience company developing therapies for neuropsychiatric disorders, including anxiety and cognitive impairments, with a focus on first-in-class and best-in-class treatments.

Series A
$93.5M
02/13/2025
Article
T
Tines

Workflow automation • AI-powered features

Goldman Sachs Alternatives logo
SoftBank Investment Advisers logo
Felicis logo
CrowdStrike logo

Tines provides a workflow automation platform used by security, engineering, and IT teams to streamline processes and enhance productivity.

Series C
$125M
02/11/2025
Article
N
NYSHEX

Container shipping • Contract fulfillment

Collate Capital logo
NewRoad Capital logo
Intercontinental Exchange logo
Goldman Sachs Alternatives logo

The New York Shipping Exchange (NYSHEX) provides a technology platform to improve contract fulfillment and reduce economic waste in the container shipping industry.

Series C
Undisclosed
11/20/2024
Article
S
Simbe

Retail technology • Autonomous robots

Goldman Sachs Alternatives logo
Valo Ventures logo
Eclipse logo

Simbe develops advanced autonomous robots and software solutions to enhance retail operations through item-scanning and data insights.

Series C
$50M
11/06/2024
Article
S
Seaport Therapeutics

Neuropsychiatric • Medicines

General Atlantic logo
T. Rowe Price Associates logo
Sofinnova Investments logo
Third Rock Ventures logo

Seaport Therapeutics develops neuropsychiatric medicines using its Glyph technology platform to enhance oral bioavailability and reduce side effects, with a focus on treating depression, anxiety, and other disorders.

Series B
$225M
10/22/2024
Article
B
BrightNight

Renewable energy • Power platform

Goldman Sachs Alternatives logo

BrightNight is a U.S. renewable power platform focused on delivering clean, dispatchable power solutions.

Hybrid
$840M
10/07/2024
Article
T
Triveni Bio

Biotech • Antibody treatments

Goldman Sachs Alternatives logo
Viking Global Investors logo
OrbiMed logo
Invus logo

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Series B
$115M
10/02/2024
Article
V
Vicebio

Biopharmaceutical • Vaccines

TCGX logo
venBio logo
UniQuest logo
Medicxi logo

Vicebio Ltd is a biopharmaceutical company developing next-generation multivalent respiratory virus vaccines using proprietary Molecular Clamp technology.

Series B
$100M
09/23/2024
Article